Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;8(5):529-539.
doi: 10.21037/tau.2019.10.01.

Epidemiology and treatment modalities for the management of benign prostatic hyperplasia

Soum D Lokeshwar  1 , Benjamin T Harper  2 , Eric Webb  2 , Andre Jordan  1 , Thomas A Dykes  3 , Durwood E Neal Jr  2 , Martha K Terris  2   3 , Zachary Klaassen  2
Affiliations
Review

Epidemiology and treatment modalities for the management of benign prostatic hyperplasia

Soum D Lokeshwar et al. Transl Androl Urol. 2019 Oct.

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men. BPH can lead to a number of symptoms for patients commonly referred to as lower urinary tract symptoms (LUTS). Over the last decade, increased modifiable risk factors, such as metabolic disease and obesity, have resulted in an increased incidence of BPH. This increasing incidence has brought about a multitude of treatment modalities in the last two decades. With so many treatment modalities available, physicians are tasked with selecting the optimal therapy for their patients. Current therapies can first be divided into medical or surgical intervention. Medical therapy for BPH includes 5-alpha-reductase inhibitors and alpha-blockers, or a combination of both. Surgical interventions include a conventional transurethral resection of the prostate (TURP), as well as newer modalities such as bipolar TURP, holmium laser enucleation of the prostate (HoLEP), Greenlight and thulium laser, and prostatic urethral lift (PUL). Emerging therapies in this field must also be further investigated for safety and efficacy. This narrative review attempts to consolidate current and emerging treatment options for BPH and highlights the need for additional investigation on optimizing treatment selection.

Keywords: BPH epidemiology; Benign prostatic hyperplasia (BPH); future therapies; urologic surgery.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

    1. Management of Benign Prostatic Hyperplasia. American Urological Association 2010. Available online: https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-gui...
    1. McNeal JE. The zonal anatomy of the prostate. Prostate 1981;2:35-49. 10.1002/pros.2990020105 - DOI - PubMed
    1. Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep 2010;5:212-8. 10.1007/s11884-010-0067-2 - DOI - PMC - PubMed
    1. De Nunzio C, Roehrborn CG, Andersson KE, et al. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus 2017;3:352-63. 10.1016/j.euf.2017.11.004 - DOI - PubMed
    1. Chapple CR. Anatomy and Innervation of the Prostate Gland. In: Chapple CR. editor. Prostatic Obstruction: Pathogenesis and Treatment. London: Springer London, 1994:5-76.